As of 2025-05-16, the Relative Valuation of Denali Therapeutics Inc (DNLI) is (78.16) USD. This relative valuation is based on P/E multiples. With the latest stock price at 14.16 USD, the upside of Denali Therapeutics Inc based on Relative Valuation is -652.0%.
The range of the Relative Valuation is (67.82) - (112.01) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.4x - 38.5x | 24.6x |
| Forward P/E multiples | 23.3x - 45.6x | 29.1x |
| Fair Price | (67.82) - (112.01) | (78.16) |
| Upside | -579.0% - -891.0% | -652.0% |
| Date | P/E |
| 2025-05-15 | -4.86 |
| 2025-05-14 | -4.80 |
| 2025-05-13 | -4.90 |
| 2025-05-12 | -5.08 |
| 2025-05-09 | -4.94 |
| 2025-05-08 | -4.96 |
| 2025-05-07 | -4.92 |
| 2025-05-06 | -4.80 |
| 2025-05-05 | -5.49 |
| 2025-05-02 | -5.65 |
| 2025-05-01 | -5.52 |
| 2025-04-30 | -5.72 |
| 2025-04-29 | -5.67 |
| 2025-04-28 | -5.58 |
| 2025-04-25 | -5.39 |
| 2025-04-24 | -5.32 |
| 2025-04-23 | -5.11 |
| 2025-04-22 | -5.02 |
| 2025-04-21 | -4.52 |
| 2025-04-17 | -4.38 |
| 2025-04-16 | -4.31 |
| 2025-04-15 | -4.52 |
| 2025-04-14 | -4.56 |
| 2025-04-11 | -4.36 |
| 2025-04-10 | -4.29 |
| 2025-04-09 | -4.42 |
| 2025-04-08 | -3.94 |
| 2025-04-07 | -3.99 |
| 2025-04-04 | -4.05 |
| 2025-04-03 | -4.39 |
| 2025-04-02 | -4.72 |
| 2025-04-01 | -4.22 |
| 2025-03-31 | -4.67 |
| 2025-03-28 | -5.08 |
| 2025-03-27 | -4.88 |
| 2025-03-26 | -4.74 |
| 2025-03-25 | -4.85 |
| 2025-03-24 | -5.07 |
| 2025-03-21 | -4.96 |
| 2025-03-20 | -5.02 |
| 2025-03-19 | -5.09 |
| 2025-03-18 | -4.98 |
| 2025-03-17 | -5.30 |
| 2025-03-14 | -5.20 |
| 2025-03-13 | -5.12 |
| 2025-03-12 | -5.48 |
| 2025-03-11 | -5.17 |
| 2025-03-10 | -5.14 |
| 2025-03-07 | -5.73 |
| 2025-03-06 | -5.59 |